可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Romano M,Buffoli F,Tomasi L,et al.The no-reflow phenomenon in acute myocardial infarction after primary angioplasty: incidence, predictive factors, and long-term outcomes[J].J Cardiovasc Med,2008, 9(1):59-63.
[2]李丹,王祖锦,王岚峰,等.冠状动脉内注射腺苷对急性心肌梗死再灌注后无复流的影响[J].心脏杂志,2009,21(3):371-374.
[3]赵红艳.腺苷在急性心肌梗死再灌注中的作用[J].中国实用医药,2009,4(10):71- 72.
[4]Movahed MR,Baweja G.Distal administration of very high doses of intracoronary adenosine for the treatment of resistant no-reflow[J].Exp Clin Cardiol,2008,13(3):141-143.
[5]Pan W,Wang LF,Yu JH,et al.Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction[J].Chin Med J,2009,122(22): 2718-2723.
[6]Amit G,Cafri C,Yaroslavtsev S,et al.Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction, A randomized, double-blind, placebo-controlled clinical trial[J].Am Heart J,2006,152(5):887,e9-e14.
[7]王智,唐强,唐群中,等.急诊经皮冠状动脉介入治疗前冠脉内注射盐酸替罗非班对急性ST段抬高型心肌梗死患者术中TIMI血流的影响[J].中国介入心脏病学杂志,2009,17(1):17-19.
[8]王惠萍,陈桂英,周立君,等.替罗非班对急性心肌梗死经皮冠状动脉介入治疗中无复流现象的影响[J].中华心血管病杂志,2007,12(6):420-423.
[9]Iwakura K,Ito H,Okamura A.Nicorandil treatment in patients with acute myocardial infarction:a meta-analysis[J].Circ J,2009,73(5):925 -931.
[10]赵鹏,姜铁民,赵季红,等.经微导管注射维拉帕米对急诊PCI术中无复流现象的疗效[J].临床荟萃,2009,24(1):19-22.
[11]张书富,郑鹏翔,陈德,等.地尔硫卓艹治疗直接经皮冠状动脉介入术无复流的临床研究[J].老年医学与保健,2008,14(2):123-124.
[12]赵希军,刘现亮,何国祥,等.单剂量阿托伐他汀对兔急性心肌梗死再灌注后内皮素-1及无复流的影响[J].实用医学杂志,2008,24(22):3833-3835.
[13]Yang YJ,Zhao JL,You SJ,et al. Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel[J].Eur J Heart Fail,2007,9(1):30-36.
[14]Zhao JL,Yang YJ,Pei WD,et al.The effect of statins on the no-reflow phenomenon,an observational study in patients with hyperglycemia before primary angioplasty[J].Am J Cardilvasc Drugs,2009,9(2):81-89.
[15]Zhao JL,Yang YJ,Cui CJ, et al. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel[J].Br J Pharmacol,2006,149(3):243-249.